Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
Enveric Bioscience, a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today highlighted preclinical data for its lead candidate, EB-003[cite: 318]. EB-003 is a dual 5-HT 2A and 5-HT 1B modulator; in recent studies, a single dose significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05)[cite: 318]. These results indicate a rapid reduction in conditioned fear response in a validated preclinical model of post-traumatic stress disorder (PTSD)[cite: 319].
Federal Recognition and Shifting Paradigms
President Donald Trump's April 18, 2026, Executive Order supporting research into psychedelic therapies for mental health conditions, including PTSD, highlights increasing recognition at the federal level of the urgent need for novel treatment approaches[cite: 320].
"In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression," stated President Trump[cite: 321].
Secretary of Health and Human Services Robert F. Kennedy Jr commented, "At the same time, millions of Americans living with depression, PTSD, addiction and other conditions do not respond to existing treatments." [cite: 322]
Strategic Positioning and Mechanism of Action
Joseph Tucker, Ph.D., CEO of Enveric Biosciences, stated: "We believe Enveric's portfolio of neuroplastogenic compounds, such as EB-003, is well positioned to meet the challenges recognized by regulators and provide therapeutic solutions that fit within existing patient treatment approaches while avoiding real-world limitations of delivering traditional hallucinogenic psychedelic therapies, which may require specialized clinical infrastructure." [cite: 323]
"Enveric's EB-003 findings in a model of PTSD highlight the potential importance of targeting both neuroplasticity and mood signaling pathways," Dr. Tucker continued[cite: 324]. "We believe EB-003's combined activity at 5-HT 2A and 5-HT 1B receptors may offer a differentiated approach to promoting neuroplasticity while restoring key signaling pathways involved in emotional regulation and stress response." [cite: 325]
EB-003 is designed as a next-generation neuroplastogen that combines partial agonism at the 5-HT 2A receptor with concomitant agonism of the 5-HT 1B receptor[cite: 326]. Prior studies have reported that reduced 5-HT 1B receptor expression and function in key brain regions is associated with increased severity of PTSD symptoms, enhanced comorbidity with major depressive disorder, and greater lifetime trauma burden[cite: 327]. Activation of 5-HT 2A receptors has been associated with increased neuroplasticity in brain regions involved in cognition, emotional regulation and decision making[cite: 328]. Together, these mechanisms may enable differentiated therapeutic benefit in PTSD and other neuropsychiatric disorders[cite: 329].
About Enveric Biosciences
Enveric Biosciences is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders[cite: 331]. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects[cite: 332]. Enveric's lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT 2A and 5-HT 1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience[cite: 333].
